EXOR INVESTOR DAY **30 NOVEMBER 2023**



Certain statements and information contained in this presentation that are not statements or information of historical fact constitute forward-looking statements, notwithstanding that such statements are not specifically identified. These forward-looking statements may include statements regarding our (or our portfolio companies') plans, objectives, goals, strategies, future events, future revenue or performance, financing needs, plans or intentions relating to acquisitions, investments or capital expenditures, business trends or other information that is not historical information. These statements may include terminology such as "may", "will", "expect", "could", "should", "intend", "estimate", "anticipate", "believe", "remain", "on track", "design", "target", "objective", "goal", "forecast", "projection", "outlook", "prospects", "plan", "intend", or similar terminology. Forward-looking statements are related to future, not past, events and are not guarantees of future performance. These statements are based on current expectations, assumptions and projections about future events and, by their nature, address matters that are, to different degrees, uncertain and are subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future, and, as such, undue reliance should not be placed on them. Actual results may differ materially from those expressed in such statements as a result of a variety of factors, including among others:

- changes in general economic, financial and market conditions and other changes in business conditions;
- changes in commodity prices, the level of demand and financial performance of the major industries our portfolio companies serve; and
- changes in regulations and institutional framework (in each case, in Italy or abroad); and
- many other factors, most of which are outside of the control of EXOR.

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements included in EXOR's Annual Report 2022, including those set forth under the heading "Risk Factors". These risks and uncertainties, as well as other risks of which we are not aware or which we currently do not believe to be material, may cause our actual future results to be materially different than those expressed in our forward-looking statements.

Investors and shareholders are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements speak only as of the date they are made. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. EXOR undertakes no obligation to update or revise its outlook or forward-looking statements, whether as a result of new developments or otherwise. EXOR expressly disclaims and does not assume any liability in connection with any inaccuracies in any of these forward-looking statements or in connection with any use by any party of such forward-looking statements.

Names, organizations and company names referred to may be the trademarks of their respective owners.

This presentation does not represent investment advice neither a solicitation, nor a recommendation nor an invitation, nor an offer for the purchase or sale of financial products and/or of any kind of financial services as contemplated by the laws in any country or state.



AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT'S NEXT?

IN 2023 WE CONTINUED TO EXECUTE ON OUR PRIORITIES



COMPANIES

- Became a long-term investor in Philips, a global leader in health technology, and built a 15% stake
- Joined forces with Impala to develop TagEnergy, a fast-growing company in the renewal energy space
- Committed to participate in the Juventus capital increase
- Increased investment in Via Transportation

INVESTMENTS

- Launched Lingotto as an independent alternative investment manager with \$4.5bn AuM contributed by Covéa and Exor
- Continued our investments in Exor Ventures

FINANCE


- Announced a new €1bn share buyback program
- Managed our financial position efficiently, with rating upgraded to A- by S&P

ESG

- Published our first TCFD report
- Expanded our education initiatives

WE HAVE REDEPLOYED THE PARTNER RE SALE PROCEEDS





¹⁾ Including proceeds from the sale of Partner Re, cash and cash equivalents and listed securities at 2021YE and Net FCF in 2022-24.

²⁾ Including amount invested in Philips, Institut Merieux, TagEnergy, Juventus, Lifenet, Via, Casavo, ShangXia and NUO.

³⁾ Including amount invested in Lingotto Funds and Ventures.

⁴⁾ Corresponding to €0.6bn maturing bond in December 2022, redeemed in October 2022 pursuant to the pre-maturity call option.

⁵⁾ Including other assets of which €0.4bn reinsurance vehicles expected to mature after 2024.

⁶⁾ Including amount allocated to Institut Merieux (€0.55bn), Lingotto Funds (€0.35bn), Ventures (€0.42bn) and the remaining amount allocated to Buyback not yet funded (€0.25bn), among others. Note: Numbers may not add due to rounding.



AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT'S NEXT?

OUR THREE LARGEST COMPANIES CONTINUE TO PROGRESS ON THEIR STRATEGIC PLANS


















We will continue to support our Companies as they pursue their paths to greatness

WE HAVE CONTINUED TO LOOK FOR NEW COMPANIES IN OUR THREE PRIORITY SECTORS





We also remain open to new sectors and geographies where we can build great companies with great people

WE HAVE DEEPENED OUR KNOWLEDGE OF HEALTHCARE



LONG-TERM SUPPORTING TRENDS

Healthcare expenditure has nearly tripled in value since 2000 to +\$9tn and represents ~10% of global GDP



Pro capita healthcare expenditure doubled in the last 20 years and is expected to continue rising



Growth in healthcare expenditure is expected to continue benefitting from the global ageing population



Long-term shareholders are rewarded as all healthcare subsectors outperformed the MSCI World over a multidecade timeframe

AREAS WE ARE EXPLORING:



Healthcare Services



COMPANIES

VENTURES

Life Sciences Tools



Imaging & Instruments



Diagnostics



Life Science Ingredients, e.g. genomics and proteomics



Precision Medicine



Robotics & Automation



Al-enabled Medicine



Biomanufacturing



Pharma services

OUR INVESTMENT IN PHILIPS IS OUR LARGEST HEALTHCARE INVESTMENT





€2.8bn investment

15% ownership

Right to nominate 1 Director

Closed on 14 August 2023

STRONG ALIGNMENT WITH PHILIPS MANAGEMENT TEAM



"Exor's investment in Philips, their long-term outlook and increased focus on healthcare and technology, fit well with our strategy and substantial value creation potential. With our market leadership positions and peoplecentric innovation capabilities, Philips is well positioned to deliver on our purpose to improve the health and well-being of people, creating value for all stakeholders." – Roy Jakobs (Philips CEO)



"We welcome Exor as a long-term investor in Philips. They have a successful track record and clear strategy to grow and develop in healthcare and technology. Exor's substantial investment underlines their confidence in Philips' transformation into a healthcare technology company and its growth and value potential." — Feike Sijbesma (Philips Chair)

"The path of change taken by Philips in recent years has created a company that combines two areas – healthcare and technology – to which we are committed.


Our discussions have confirmed the strong and positive alignment between our long-term, supportive approach to our companies and Philips' ambitious plans under the chairmanship of Feike Sijbesma and the executive team led by Roy Jakobs." – John Elkann (Exor CEO)



PHILIPS HAS SUCCESSFULLY REPOSITIONED ITSELF IN THE HEALTHCARE DOMAIN, AND IS CURRENTLY MANAGING A SET OF CHALLENGES



SALES (€BN) AND SHARE PRICE EVOLUTION (€)



PHILIPS IS WELL POSITIONED IN ATTRACTIVE SEGMENTS






DIAGNOSIS & TREATMENT

CONNECTED CARE

PERSONAL HEALTH











Addressable Market (€bn)







MARKET POSITIONING¹



- #1 Global in Cardiac Ultrasound
- Top 3 Global in Diagnostic Imaging



- #1 in Ambulatory monitoring
- Leader in Enterprise Informatics (#1 in Imaging, PACS & interoperability)
- #2 Global in Sleep & Respiratory Care



- #2 Global in Oral Healthcare
- #2 Global in Infant Feeding

OUR INVESTMENT ENABLES US TO EXPAND OUR PRESENCE IN HEALTHCARE







Largest shareholder in a large-scale public company exposed to both healthcare and technology





Leadership position in attractive niche markets as well as growing exposure to informatics





Long-term potential at an attractive price





Targets a return to healthy top-line growth and profitability





Management team committed to overcoming current difficulties and building a great company

PHILIPS BECOMES THE FOURTH LARGE COMPANY IN OUR PORTFOLIO








AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT'S NEXT?

WE HAVE INVESTED ~\$0.6BN ACROSS A BALANCED VENTURES PORTFOLIO Exor





WE HAVE LAUNCHED VENTO: THE ITALIAN CHAPTER OF EXOR VENTURES



	EARLY-STAGE INVESTING	VENTURE BUILDING		
VISION	✓ The most recognized program for early-stage (pre- seed & seed) Italian entrepreneurs	✓ Back the brightest minds to launch ventures		
GOAL	 ✓ Invest in 50%+ of the best new companies over the next 10 years ✓ Close 100 deals/year (€15mn/year) 	✓ At least five new Vento companies enter the portfolio each year		
ECONOMICS	✓ €150k investment for mid single-digit ownership	✓ €80k convertible note with €800k post-money cap		
OUR VALUE PROPOSITION	 ✓ Speed: Efficient process ✓ Brand: High quality investor ✓ Community: Strong network of founders, top-tier investors, and corporates ✓ Global reach: Help founders think globally 	 ✓ Network: Strong network of mentors, entrepreneurs and top-tier investors ✓ Grant: Support Founders to participate full time ✓ Potential investment: Opportunity to receive a preseed check 		
RESULTS	✓ 2,158 applications since April 2022✓ 55 companies backed	 ✓ 1,000+ applications received in the last 2 cohorts ✓ 20 new companies incorporated, 10 backed by Vento 		



Lingotto Overview

November 2023

Introduction to Lingotto

Who We Are

Lingotto is an independent alternative investment manager, that was launched in May 2023, and is wholly owned by Exor

Two Founding investors: Exor and Covéa

~\$4.5bn1 AUM

3 core strategies

~40 investment and business professionals

Offices in London and New York

Our Objective

"We are committed to delivering attractive long-term returns to our limited partners, protecting their capital from permanent losses while accepting concentration, illiquidity and volatility".

John Elkann (Founder)

We think and act as principals rather than agents; investing alongside those who entrust their money to us


Our Differentiated Approach



Lingotto Values

Courage & Responsibility

Having conviction in our differentiated analysis whilst embracing concentration and maintaining full accountability



Ambition & Humility

Encouraging diversity of opinion and rigorous thinking, we aim to deliver uncorrelated results

Curiosity & Focus

Appreciating the unexplored and the unconventional, while avoiding short-termism

Patience & Drive

Accepting volatility as an opportunity and not a risk, firmly believing in the benefits of long-term investing

Culture rooted in transparency, autonomy and cooperation

Strategies and Managing Partners/CIOs

~\$4.5bn¹ Assets Under Management Today

LONG/SHORT EQUITY Matteo Scolari

20 years investment experience

Former Eton Park Portfolio Manager

Goldman Sachs and McKinsey

Wharton MBA, Palmer Scholar

NAV ~2,400m¹

- Strategy: Public equity, on concentrated long only and long/short basis
- bottom-up approach; Fundamental bottom-up approach, long-term analysis, concentrated portfolio
- Geography: Predominantly developed markets

OPPORTUNITY Nikhil Srinivasan

20 years investment experience

Former CIO: Allianz, Generali, PartnerRe

Twice supervised ~\$500bn in assets

NAV ~1,600m²

- Strategy: Investments across the full capital structure, mostly in private companies
- Investment approach: Special situation opportunities in idiosyncratic niches
- Geography: Global with a bias to Europe & Asia

INNOVATION James Anderson



40 years investment experience

Partner Baillie Gifford (1987 - 2022)

Former co-manager Vanguard Intl Growth Fund & Scottish Mortgage Investment Trust.

Chair of Kinnevik AB

NAV ~500m¹

- **Strategy:** Primarily public equity with some private equity, on a long-only basis
- structural winners, concentrated, longterm commitment
- **Geography:** Global

Strategic and Operational Progress

	Progress in 2023	Future Priorities	
STRATEGIES	'Opportunity' launched in Q1 2023 'Innovation' launched in Q2 2023	Launch new strategies selectively	
	New joiners - Investment Teams Managing Partner and CIO, Partners and Analysts	Continue to recruit high quality talent	
PEOPLE	New joiners - Business COO, Investor Relations, Trading and Operations	Enhance the organization while minimising bureaucracy	
	Board of Directors - George Osborne appointed as Chair		
	Offices - New locations in London and New York	Expand global presence of our investment teams	
INVESTORS	Engaged prospective investors	Build long-term partnerships with selected investors	



AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT'S NEXT?

WE HAVE CONTINUED TO DELIVER ON OUR TARGETS



		Our Targets	2023YTD ¹	Last 5 years ²
OBJECTIVES	NAV/Share growth %	Outperform MSCI World Index	~28% vs. MSCI: ~13%	~63% vs. MSCI: ~51%
	TSR CAGR %	8%	~32%	~8%
EXOR KPIs	FCF ³ / Dividend paid	Above 1.0x	~7.0x	~3.0x
	Holding cost ⁴ / GAV	Below 10bps	~7bps	~6bps
	Loan To Value ratio %	Below 20%	~10%	~8%

As of 23 November. KPI figures related to FCF and holding cost are annualized.
 Last 5 years as presented in the November 2022 presentation.

FCF defined as dividend inflow – net general expenses – net financial income (expenses).

Cash based holding cost.

WE ARE DISCIPLINED IN HOW WE ALLOCATE CAPITAL WHILE ENSURING A STRONG BALANCE SHEET AND A STABLE DIVIDEND



Companies

- Invest in existing companies
- Acquire new companies that have the potential to become great
- Consider company exits if we are no longer the best owner

Investments

- Invest in Ventures, with exposure to early and latestage opportunities
- Invest in Lingotto Funds, with exposure to public and private market strategies
- Assess allocation to Investments

Buyback

 Invest in our own shares when terms are attractive

We use a Portfolio Review Process to monitor and assess our portfolio and drive capital allocation decisions

WE HAVE TAKEN ADVANTAGE OF OUR DISCOUNT TO NAV TO INVEST IN OUR PORTFOLIO



- New share buyback program of €1bn announced in September, bringing total share buyback to €1.5bn between 2022 and 2024
- Tender offer for an amount of €750mn launched on 14 September
 - Oversubscribed and priced at zero premium to reference price
 - Acquired shares represented 3.8% of share capital
- Share cancellation process of 5.6% of share capital¹ has started, with effective cancellation in H1 2024
- Regular on-market buyback for the remaining €250mn to continue in 2024

Buybacks are an integral part of our capital allocation framework


WE FOCUS ON EFFICIENT DEBT MANAGEMENT, SUPPORTED BY A RATING UPGRADE TO A-




Current Gross Debt^{1,2} ~€3.7bn



WELL BALANCED MATURITY PROFILE





All figures are expressed in millions and in the original currency of issuance

- Solid capital structure, with Exor's rating recently upgraded by S&P
- Majority in Euro (~95%) and made up of bonds with average maturity ~6 years and average fixed cost ~2.5%
- Constant efforts to balance financing across different sources, maturity profiles and amounts
- 1) Including bond debt and bank debt, excluding other financial liabilities (€0.6bn).
- 2) Excluding accrued interest and amortized cost.
- Exor put in place a cross-currency swap on the bond issue.



AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT'S NEXT?

WE ARE CONTINUING TO MAKE SIGNIFICANT PROGRESS AROUND OUR ESG PASSIONS



OUR PASSIONS

COMMITMENTS AT HOLDING LEVEL

OUR PROGRESS



 Achieve carbon neutrality by 2022 and net zero emissions by 2025

- ✓ Published our first TCFD Report
- ✓ Carbon neutral since FY2021



- Reduce the gender gap in STEM subjects
- Help high potential young entrepreneurs
- ✓ National launch of Matabì initiative with 130 classes involved across 6 regions in Italy
 FOCUS OF NEXT SLIDE
- ✓ Working with Innovation 4 Change to support the entrepreneurs of the future



 Maintain 40/60 gender balance and consider diverse candidates for all new appointments

- √ 41/59 gender balance
- ✓ Carried out first unconscious bias training workshop for all employees


We have continued to expand our networks of excellence and knowledge-sharing across our Companies

IN 2023, WE SCALED UP OUR MATABÌ INITIATIVE THAT AIMS TO REDUCE THE GENDER GAP IN STEM SUBJECTS



Understanding Matabi

Aim: Reduce the gender gap in STEM subjects



Audience: Primary school pupils & teachers



Activities: Classroom activities using Lego-Duplo kits & teacher training



WHAT HAVE WE BEEN BUILDING IN 2023/24?

NATIONAL ROLLOUT



- Publicly launched in Naples
- 130 classes from 25 schools in 6 Italian regions
- Special impact assessment framework
- Roadshow on the role of women in STEM



Matabì is carried out by Fondazione Agnelli







The **LEGO** Foundation



AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT'S NEXT?

WE WILL CONTINUE TO FOCUS ON OUR PRIORITIES



✓ Remain a long-term and active shareholder, aligning ownership, governance and leadership




✓ Strengthen our investment capabilities through Exor Ventures and Lingotto

✓ Continue to explore new opportunities

✓ Maintain discipline in capital allocation, while ensuring a strong balance sheet







Q&A SESSION